Loading
A tool that takes one patient's tumour genetics and gives the probability that it belongs to each of seven genetic groups, rather than sorting whole cohorts into clusters.
Clustering methods classify a cohort. A patient needs a classification of their own tumour, with a statement of how confident it is. LymphGen is the algorithm that provides it: it returns the probability that a given lymphoma belongs to each of seven genetic subtypes on the basis of its genetic features.
The classification extends the four subtypes of the 2018 National Cancer Institute paper and revealed genetic similarities between diffuse large B-cell lymphoma subtypes and various indolent and extranodal lymphoma types, which suggests a shared pathogenesis and is one of the stronger arguments that the current histological boundaries do not cut the disease at its joints. The subtypes have distinct gene-expression profiles, distinct immune microenvironments and distinct outcomes after immunochemotherapy, and functional analysis of subtype models showed distinct vulnerabilities to targeted therapy.
LymphGen is now the classifier used to select patients in genetics-directed trials in this disease, which is the practical reason it belongs on this list rather than in a methods appendix.
The piece that turns a research classification into something a trial can use on one person's biopsy, with a probability attached rather than a flat label. It is the reason genetics-directed lymphoma trials became possible at all.
The genetic nosology that precision-medicine trials in diffuse large B-cell lymphoma now use to pick patients. It gives a mechanism, not just a label: two of the four subtypes point at a drug class that already exists.
One of the two foundational genetic classifications of diffuse large B-cell lymphoma. Neither has yet changed what a patient receives outside a trial, but together they are the reason precision-medicine trials in this disease now select by genetics rather than by cell of origin.
The practical form of cell-of-origin classification, used in pathology laboratories worldwide. When a report says germinal-centre or non-germinal-centre, this is almost always the algorithm behind it.
Shares Louis M. Staudt, Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, BCL6, Genetics and pathogenesis of diffuse large B-cell lymphoma and the tag lymphoma-evidence.
Shares Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Assign first-line treatment in diffuse large B-cell lymphoma by genetic subtype, not by a three-antibody stain, Genetics and pathogenesis of diffuse large B-cell lymphoma, Cell of origin (GCB vs ABC) and the tag lymphoma-evidence.
Shares Cell of origin (GCB vs ABC), Next-generation sequencing (NGS), Whole-exome & whole-genome sequencing, Biomarkers are not validated or standardised and the tag lymphoma-evidence.
Shares Genetics and pathogenesis of diffuse large B-cell lymphoma, Cell of origin (GCB vs ABC), Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma and the tag lymphoma-evidence.
Shares Next-generation sequencing (NGS), Biomarkers are not validated or standardised, Trial design, endpoints and cost, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares Cell of origin (GCB vs ABC), Biomarkers are not validated or standardised, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma and the tag lymphoma-evidence.
Shares Cell of origin (GCB vs ABC), Biomarkers are not validated or standardised, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma and the tag lymphoma-evidence.
Shares Trial design, endpoints and cost, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, National Cancer Institute (NIH), Diffuse large B-cell lymphoma and the tag lymphoma-evidence.